Eli Lilly's Foundayo Shows Superior Weight Loss Results; LLY Stock Modestly Undervalued
· gurufocus.com
On September 29, 2026, Eli Lilly and Co (NYSE: LLY) announced that its oral weight-loss drug, Foundayo (orforglipron) 17.2 mg, demonstrated superior efficacy in
On September 29, 2026, Eli Lilly and Co (NYSE: LLY) announced that its oral weight-loss drug, Foundayo (orforglipron) 17.2 mg, demonstrated superior efficacy in...